Saving New Crown Patients FDA Allows Experimental Program: Plasma Therapy

Recently, the FDA of the U.S. Food and Drug Administration updated the experimental program of new coronary therapy, adding plasma therapy. Plasma therapy refers to the treatment of extracting plasma from a cured new coronary patient and transferring it to the patient, because the cured patient has produced a new coronavirus antibody, will not be infected with the new coronavirus in the short term, the plasma into the patient’s body, may also help the patient produce the same antibody to fight the virus.

However, the therapy has not been clinically proven, and the FDA approves plasma therapy only in emergency situations where the patient’s life is seriously threatened.

A number of domestic hospitals and research teams as early as February have adopted this treatment, and achieved a pretty good treatment effect, including the Chinese medicine Chinese biological to take the new coronary pneumonia rehabilitation plasma treatment research team in Wuhan to treat nearly 50 seriously ill patients, 6 patients have been discharged, most of the patients have improved, will be discharged in the near future.

Data show that donating plasma once can save 2-3 new corona patients.

In addition, studies have shown that normal people can also have a preventive effect when they enter plasma, but the FDA explicitly prohibits its use for any preventive purpose.

Saving New Crown Patients FDA Allows Experimental Program: Plasma Therapy